Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Catalyst Pharmaceuticals (CPRX) Equity Average: 2011-2025

Historic Equity Average for Catalyst Pharmaceuticals (CPRX) over the last 12 years, with Sep 2025 value amounting to $888.1 million.

  • Catalyst Pharmaceuticals' Equity Average rose 39.91% to $888.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $888.1 million, marking a year-over-year increase of 39.91%. This contributed to the annual value of $557.8 million for FY2024, which is 62.07% up from last year.
  • Per Catalyst Pharmaceuticals' latest filing, its Equity Average stood at $888.1 million for Q3 2025, which was up 7.63% from $825.2 million recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Equity Average registered a high of $888.1 million during Q3 2025, and its lowest value of $174.1 million during Q1 2021.
  • Moreover, its 3-year median value for Equity Average was $585.0 million (2024), whereas its average is $569.5 million.
  • Data for Catalyst Pharmaceuticals' Equity Average shows a peak YoY surged of 88.55% (in 2024) over the last 5 years.
  • Over the past 5 years, Catalyst Pharmaceuticals' Equity Average (Quarterly) stood at $202.7 million in 2021, then soared by 40.68% to $285.2 million in 2022, then grew by 29.09% to $368.2 million in 2023, then surged by 88.55% to $694.3 million in 2024, then spiked by 39.91% to $888.1 million in 2025.
  • Its last three reported values are $888.1 million in Q3 2025, $825.2 million for Q2 2025, and $761.0 million during Q1 2025.